Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg/ml - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - doxorubicin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - doxorubicin hydrochloride 2 mg/ml;  ;  ;   - solution for injection - 2 mg/ml - active: doxorubicin hydrochloride 2 mg/ml       excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. doxorubicin hydrochloride injection is indicated for the treatment of - acute lymphoblastic leukemia - acute myeloblastic leukemia - hodgkin lymphoma - non-hodgkin lymphoma (nhl) - metastatic breast cancer - metastatic wilms’ tumor - metastatic neuroblastoma - metastatic soft tissue sarcoma - metastatic bone sarcoma - metastatic ovarian carcinoma - metastatic transitional cell bladder carcinoma - metastatic thyroid carcinoma - metastatic gastric carcinoma - metastatic bronchogenic carcinoma doxorubicin hydrochloride injection is contraindicated in patients with: - severe myocardial insufficiency [see warnings and precautions (5.1)] - recent (occurring within the past 4 to 6 weeks) myocardial infarction [see warnings and precautions (5.1)] - severe persistent drug-induced myelosuppression [see warnings and

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride injection, usp is indicated as a c omponent of multi-a gent adjuvant chemotherapy for treat ment of wo men with axillary lymph node involve ment following resection of pri mary breast cancer [see clinical studies (14.1 ) ]. doxorubicin hydrochloride injection, usp is indicated for the treat ment of - acute ly mphoblastic leu ke mia - acute m yeloblastic leuke mia - hodgkin lympho ma - non-hodgkin ly mpho ma (nhl) - metastatic breast cancer - metastatic wil ms’ tumor - metastatic neurobla stoma - metastatic s oft tissue sa rco ma - metastatic bone sarco ma - metastatic o varian car cino ma - metastatic t ransitional c ell bladder carcino ma - metastatic t hyroid carcinoma - metastatic gastric carcinoma - metastatic bronchogenic carcinoma doxorubicin hydrochloride is contraindicated in patients with: - severe myocardial insufficiency [see warnings and precautions (5.1)] - recent (occurring within the past 4 to 6 weeks) myocardial infarction [see warnings and precautions

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - doxorubicin hydrochloride 2 mg/ml - concentrate for infusion - 2 mg/ml - active: doxorubicin hydrochloride 2 mg/ml excipient: hydrochloric acid sodium chloride water for injection - doxorubicin has produced significant therapeutic responses in a number of solid tumours and haematologic malignancies, and is commonly used in the treatment of the following tumours: · carcinoma of the breast · carcinoma of the lung · carcinoma of the ovary · transitional bladder cell cancer · neuroblastoma · wilm's tumour · soft tissue sarcomas · osteosarcoma · acute lymphocytic-lymphoblastic leukaemia · acute myelogenous leukaemia · non-hodgkin's lymphoma · hodgkin's disease doxorubicin has also shown antitumour activity in the following adult and paediatric malignancies: · carcinoma of the thyroid · carcinoma of the endometrium · carcinoma of the head and neck · carcinoma of the stomach · primary heptacellular carcinoma · non-seminomatous carcinoma of the testis · carcinoma of the prostate · ewing's sarcoma · rhabdomyosarcoma · multiple myeloma · chronic leukaemias

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eugia pharma (malta) ltd. - doxorubicin hydrochloride 10 mg/5 ml - concentrate for solution for infusion - 2 mg/ml - doxorubicin hydrochloride 2 mg/ml - doxorubicin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eugia pharma (malta) ltd. - doxorubicin hydrochloride 10 mg/5 ml - concentrate for solution for infusion - 2 mg/ml - doxorubicin hydrochloride 2 mg/ml - doxorubicin